FDA approves drug to diminish bone loss in breast cancer patients
Sep 19, 2011
The U.S. Food and Drug Administration (FDA) recently announced it approved two new products of Prolia in order to treat bone loss in women who are undergoing certain types of breast cancer treatment. This makes Prolia the first therapy to reduce bone loss in cancer patients who are undergoing certain types of hormone treatment.
"Bone loss and fractures are recognized adverse effects of hormone ablation therapies but we have not had an approved treatment option to prevent these problems for our patients," said Dr. Matthew Smith, director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center. "Prolia now gives us the ability to reduce the risk of bone loss and fractures, allowing patients to continue their treatment and their fight against cancer."
According to the American Cancer Society, this disease is the second leading cause of cancer-related death among women, following only lung cancer. However, the death rate has been decreasing since 1990 due to advancements in research and breakthrough breast cancer news. There are currently 2.5 million breast cancer survivors in the U.S.